Femasys (FEMY) Competitors $0.93 -0.02 (-1.66%) As of 07/3/2025 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FEMY vs. SRTS, NSPR, APYX, ZYXI, VANI, CTSO, INO, TELA, EDAP, and MLSSShould you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Sensus Healthcare (SRTS), InspireMD (NSPR), Apyx Medical (APYX), Zynex (ZYXI), Vivani Medical (VANI), Cytosorbents (CTSO), Inovio Pharmaceuticals (INO), TELA Bio (TELA), Edap Tms (EDAP), and Milestone Scientific (MLSS). These companies are all part of the "medical equipment" industry. Femasys vs. Its Competitors Sensus Healthcare InspireMD Apyx Medical Zynex Vivani Medical Cytosorbents Inovio Pharmaceuticals TELA Bio Edap Tms Milestone Scientific Sensus Healthcare (NASDAQ:SRTS) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Do analysts rate SRTS or FEMY? Sensus Healthcare currently has a consensus target price of $11.67, suggesting a potential upside of 140.05%. Femasys has a consensus target price of $8.67, suggesting a potential upside of 827.91%. Given Femasys' higher probable upside, analysts plainly believe Femasys is more favorable than Sensus Healthcare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensus Healthcare 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SRTS or FEMY more profitable? Sensus Healthcare has a net margin of 4.56% compared to Femasys' net margin of -1,242.06%. Sensus Healthcare's return on equity of 3.34% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Sensus Healthcare4.56% 3.34% 3.00% Femasys -1,242.06%-392.45%-137.15% Does the media favor SRTS or FEMY? In the previous week, Femasys had 3 more articles in the media than Sensus Healthcare. MarketBeat recorded 3 mentions for Femasys and 0 mentions for Sensus Healthcare. Femasys' average media sentiment score of 0.92 beat Sensus Healthcare's score of 0.00 indicating that Femasys is being referred to more favorably in the news media. Company Overall Sentiment Sensus Healthcare Neutral Femasys Positive Which has preferable valuation and earnings, SRTS or FEMY? Sensus Healthcare has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Sensus Healthcare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensus Healthcare$39.49M2.02$6.65M$0.1048.60Femasys$1.63M14.64-$18.82M-$0.91-1.03 Do insiders & institutionals hold more shares of SRTS or FEMY? 25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 8.9% of Sensus Healthcare shares are owned by company insiders. Comparatively, 11.5% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, SRTS or FEMY? Sensus Healthcare has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.56, meaning that its stock price is 356% less volatile than the S&P 500. SummarySensus Healthcare beats Femasys on 10 of the 16 factors compared between the two stocks. Get Femasys News Delivered to You Automatically Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FEMY vs. The Competition Export to ExcelMetricFemasysMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.80M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-1.0321.5627.6620.25Price / Sales14.64283.36423.00177.43Price / CashN/A42.7336.8958.10Price / Book9.347.518.035.67Net Income-$18.82M-$55.14M$3.18B$249.21M7 Day Performance-4.69%4.61%2.93%3.28%1 Month Performance16.75%0.90%1.72%3.95%1 Year Performance-15.86%5.40%34.39%20.98% Femasys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FEMYFemasys3.8524 of 5 stars$0.93-1.7%$8.67+827.9%-15.9%$23.80M$1.63M-1.0330Gap DownSRTSSensus Healthcare1.5154 of 5 stars$4.60-2.7%$11.67+153.6%-9.2%$77.79M$41.81M46.0040NSPRInspireMD3.5089 of 5 stars$2.52+2.4%$4.50+78.6%-5.6%$77.20M$7.03M-3.3650News CoveragePositive NewsAPYXApyx Medical2.3506 of 5 stars$2.00flatN/A+66.2%$75.59M$48.10M-3.64270ZYXIZynex2.6198 of 5 stars$2.39-4.0%$6.00+151.0%-73.7%$75.29M$192.35M-9.96770News CoverageGap DownVANIVivani Medical2.8122 of 5 stars$1.26flat$4.00+217.5%+4.1%$74.65MN/A-2.9320High Trading VolumeCTSOCytosorbents1.9628 of 5 stars$1.26+6.8%$5.50+336.5%+14.4%$73.88M$35.60M-4.50220INOInovio Pharmaceuticals3.8621 of 5 stars$1.93-1.5%$9.75+405.2%-83.9%$71.88M$220K-0.61320News CoverageGap DownTELATELA Bio2.5772 of 5 stars$1.73+4.8%$7.25+319.1%-52.6%$65.27M$71.22M-1.23120EDAPEdap Tms2.3919 of 5 stars$1.72+1.3%$8.50+394.2%-69.0%$63.49M$69.18M-2.77230MLSSMilestone Scientific2.8959 of 5 stars$0.80-9.1%$1.25+56.4%+1.5%$62.70M$8.61M-11.4130Negative NewsGap Up Related Companies and Tools Related Companies Sensus Healthcare Alternatives InspireMD Alternatives Apyx Medical Alternatives Zynex Alternatives Vivani Medical Alternatives Cytosorbents Alternatives Inovio Pharmaceuticals Alternatives TELA Bio Alternatives Edap Tms Alternatives Milestone Scientific Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FEMY) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.